Cabaletta Bio Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
154
- Stock Symbol
-
CABA
- Share Price
-
$2.71
- (As of Friday Closing)
Cabaletta Bio General Information
Description
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Contact Information
Website
www.cabalettabio.comCorporate Office
- 2929 Arch Street
- Suite 600
- Philadelphia, PA 19104
- United States
Corporate Office
- 2929 Arch Street
- Suite 600
- Philadelphia, PA 19104
- United States
Cabaletta Bio Stock Performance
As of 14-Feb-2025, Cabaletta Bio’s stock price is $2.71. Its current market cap is $132M with 48.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.71 | $2.70 | $1.76 - $24.85 | $132M | 48.8M | 2.63M | -$2.16 |
Cabaletta Bio Financials Summary
As of 30-Sep-2024, Cabaletta Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 34,741 | 812,561 | 183,657 | (11,883) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (112,923) | (73,234) | (52,961) | (45,580) |
| Net Income | (104,164) | (67,675) | (52,975) | (46,289) |
| Total Assets | 204,410 | 253,650 | 116,968 | 126,336 |
| Total Debt | 15,224 | 5,018 | 5,138 | 0 |
Cabaletta Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cabaletta Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cabaletta Bio Comparisons
Industry
Financing
Details
Cabaletta Bio Competitors (81)
One of Cabaletta Bio’s 81 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Vera Therapeutics | Formerly VC-backed | Brisbane, CA | ||||
| Serimmune | Venture Capital-Backed | Goleta, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Second Genome | Formerly VC-backed | Brisbane, CA |
Cabaletta Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cabaletta Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cabaletta Bio ESG
Risk Overview
Risk Rating
Updated April, 24, 2024
27.75 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
Cabaletta Bio FAQs
-
When was Cabaletta Bio founded?
Cabaletta Bio was founded in 2017.
-
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Philadelphia, PA.
-
What is the size of Cabaletta Bio?
Cabaletta Bio has 154 total employees.
-
What industry is Cabaletta Bio in?
Cabaletta Bio’s primary industry is Biotechnology.
-
Is Cabaletta Bio a private or public company?
Cabaletta Bio is a Public company.
-
What is Cabaletta Bio’s stock symbol?
The ticker symbol for Cabaletta Bio is CABA.
-
What is the current stock price of Cabaletta Bio?
As of 14-Feb-2025 the stock price of Cabaletta Bio is $2.71.
-
What is the current market cap of Cabaletta Bio?
The current market capitalization of Cabaletta Bio is $132M.
-
Who are Cabaletta Bio’s competitors?
Fate Therapeutics, Vera Therapeutics, Serimmune, Adicet Bio, and Second Genome are some of the 81 competitors of Cabaletta Bio.
-
What is Cabaletta Bio’s annual earnings per share (EPS)?
Cabaletta Bio’s EPS for 12 months was -$2.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
